Maze Therapeutics, Inc.
MAZE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MAZE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MAZE
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing human genetics to develop small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 and MZE782 in early clinical development.
Key risk: No product revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.52B
Cash Runway
80.6 moLead Asset
mze001 (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials · 1 catalyst for Maze Therapeutics, Inc..
Similar companies
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing human genetics to develop small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 and MZE782 in early clinical development.
- Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing human genetics to develop small molecule precision medicines for kidney and metabolic diseases [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company had cash and equivalents of $203.7M, no product revenue, and a net loss of $44.7M for the quarter [sec].
- The company's accumulated deficit was $558.5M as of June 30, 2026, and it does not expect positive cash flows from operations for the foreseeable future [sec_mda · as of 2026-08-11].
- Lead programs MZE829 and MZE782 are in early clinical development, with a Phase 2 readout for MZE829 expected by the end of 2026 [sec_mda · as of 2026-08-11].
What works
- Maze Therapeutics leverages human genetics to develop precision medicines, a scientifically grounded approach that may increase the probability of clinical success [sec_mda · as of 2026-08-11].
- The company has a cash position of $203.7M as of June 30, 2026, providing a multi-year runway to advance its pipeline through key clinical milestones [sec].
- Maze is advancing two lead programs, MZE829 and MZE782, into clinical trials, with a Phase 2 readout for MZE829 expected by year-end 2026 [sec_mda · as of 2026-08-11].
What to weigh
- Maze Therapeutics has no product revenue and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-08-11].
- The company's accumulated deficit was $558.5M as of June 30, 2026, reflecting substantial cash consumption since inception [sec_mda · as of 2026-08-11].
- Lead programs are still in early clinical development, and the company faces the inherent risk of failure in developing therapeutic candidates based on novel technologies [sec_mda · as of 2026-03-25].
- Maze expects research and development expenses to increase significantly as it conducts planned clinical trials, which may pressure its cash runway [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing human genetics to develop small molecule precision medicines for kidney and metabolic diseases.
“We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases.”
SEC MD&A · August 11, 2026
As of June 30, 2026, the company had an accumulated deficit of $558.5 million and does not expect positive cash flows from operations for the foreseeable future.
“As of June 30, 2026, we had an accumulated deficit of $558.5 million and do not expect positive cash flows from operations for the foreseeable future.”
SEC MD&A · August 11, 2026
The company incurred a net loss of $44.7 million for the three months ended June 30, 2026.
“During the three and six months ended June 30, 2026, we incurred a net loss of $44.7 million and $68.9 million, respectively.”
SEC MD&A · August 11, 2026
Maze Therapeutics' lead programs are still in early clinical development and subject to risks of failure.
“Our lead programs are still in early clinical development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies.”
SEC MD&A · March 25, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · mze829 — Phase 2 Readout: mze829 — Topline data from the Phase 2 trial of MZE829 are expected by the end of 2026, which will be a key value inflection point for the program.
Risks & what to watch (4)›
Key risks
- No product revenue — Maze has no product revenue and expects to continue incurring significant operating losses for the foreseeable future [sec_mda · as of 2026-08-11].
- Early-stage pipeline — Lead programs MZE829 and MZE782 are in early clinical development, with inherent risk of failure [sec_mda · as of 2026-03-25].
- Substantial accumulated deficit — Accumulated deficit of $558.5M as of June 30, 2026, reflecting high cash burn [sec_mda · as of 2026-08-11].
- Increasing R&D expenses — R&D expenses expected to increase significantly with planned clinical trials, potentially pressuring cash runway [sec_mda · as of 2026-08-11].
What to watch
- Phase 2 topline data for MZE829 expected by the end of 2026 [sec_mda · as of 2026-08-11].
- Progress of MZE782 clinical trials and any updates on its development [sec_mda · as of 2026-08-11].
- Cash runway and any changes in the company's financial position or capital needs [sec_mda · as of 2026-08-11].
- Any new pipeline candidates or updates on the Compass platform [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Maze Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Maze Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
80.6 months
D/E 0.17 · 0% dilution
Lead: Phase 2
3 candidates
1 upcoming, next in ~123d
0 buys · 40 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
164
Total value held
$1.24B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 5,717,752 | $170.6M |
| arch venture management, llc | 4,120,053 | $123.0M |
| deep track capital, lp | 3,477,562 | $103.8M |
| vanguard capital management llc | 2,871,312 | $85.7M |
| blackrock, inc. | 2,570,425 | $76.7M |
| alphabet inc. | 1,388,583 | $41.4M |
| woodline partners lp | 1,300,458 | $38.8M |
| logos global management lp | 1,235,000 | $36.9M |
| adage capital partners gp, l.l.c. | 1,178,000 | $35.2M |
| general catalyst group management, llc | 1,035,910 | $30.9M |
Showing top 10 of 164 institutional holders of Maze Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.1%
- Days to cover
- 2.8
- Shares short
- 3,795,902
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MAZE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Maze Therapeutics, Inc.?
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing human genetics to develop small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 and MZE782 in early clinical development.
What is Maze Therapeutics, Inc.'s lead drug candidate?
Maze Therapeutics, Inc.'s most advanced tracked candidate is mze001 (Phase 1) for Pompe disease.
What is Maze Therapeutics, Inc.'s next catalyst?
Maze Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: mze829" — expected December 31, 2026.
Who is the CEO of Maze Therapeutics, Inc.?
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. is the chief executive officer of Maze Therapeutics, Inc. (MAZE).
Where is Maze Therapeutics, Inc. headquartered?
Maze Therapeutics, Inc. (MAZE) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.